We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Genomic Differences Cause Racial Disparities in Prostate Cancer

By LabMedica International staff writers
Posted on 17 Jun 2021
Prostate cancer is a disease defined by the abnormal growth of cells. More...
These abnormal cells can proliferate in an uncontrolled way and, if left untreated, form tumors which may metastasize or spread to other parts of the body. Prostate cancer (PCa) is the most common solid organ malignancy in men, with 174,650 new diagnoses and 31,620 deaths expected in 2019 in the USA alone.

Effective prognosis and personalized treatment regimens for PCa require identifying tumor-specific genomic factors and events and discovering disease-associated mechanisms. Although previous studies have demonstrated the existence of genomic differences between African-American (AAM) and European-American (EAM) men, the underlying mechanisms driving poor survival in AAM patients are not completely understood.

Urologists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and their colleagues analyzed a cohort of 1,152 men, 596 of whom were African American and 556 of whom were European American, and all of whom had undergone radical prostatectomy. Overall, African-American men had higher pre-treatment prostate-specific antigen levels and higher scores indicating increased risk of post-surgery recurrence, emphasizing the more aggressive disease generally found among African-American men.

From post-radical prostatectomy (RP) formalin-fixed paraffin-embedded blocks were submitted for Decipher testing. Submitted tumor tissue included the highest GG with at least 0.5 mm2 of tissue. RNA was extracted using the RNeasy kit (Qiagen, Santa Clara, CA, USA), and cDNA was prepared and amplified using the NuGEN Ovation WTA assay (NuGEN, Redwood City, CA, USA) and hybridized to Human Exon 1.0 ST microarrays (Thermo Fisher Scientific, Carlsbad, CA, USA). Quantitative real-time PCR was analyzed on the CFX384 Touch real-time PCR system (Bio-Rad Laboratories, Hercules, CA, USA).

Comparative analyses between the race groups were conducted at the clinical, genomic, pathway, molecular subtype, and prognostic levels. The EAM group had increased ERG and ETS expression, decreased SPINK1 expression, and basal-like molecular subtypes. After adjusting for confounders, the AAM group was associated with higher expression of CRYBB2, GSTM3, and inflammation genes (IL33, IFNG, CCL4, CD3, ICOSLG), and lower expression of mismatch repair genes (MSH2, MSH6).

At the pathway level, the AAM group had higher expression of genes sets related to the immune response, apoptosis, hypoxia, and reactive oxygen species. EAM group was associated with higher levels of fatty acid metabolism, DNA repair, and WNT/beta-catenin signaling. The authors concluded that their findings suggest that African-American men who undergo radical prostatectomy should be closely monitored following treatment, as they are generally at increased risk for recurrence. The study was published on June 3, 2021 in the journal Communications Biology.

Related Links:
Icahn School of Medicine at Mount Sinai
Qiagen
NuGEN
Thermo Fisher Scientific
Bio-Rad Laboratories



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.